Cargando…
The clinical potential of antiangiogenic fragments of extracellular matrix proteins
Neovasculature development is a crucial step in the natural history of a cancer. While much emphasis has been placed on proangiogenic growth factors such as VEGF, it is clear that endogenous angiogenesis inhibitors also have critical roles in the regulation of this process. Recent research has ident...
Autores principales: | Clamp, A R, Jayson, G C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361682/ https://www.ncbi.nlm.nih.gov/pubmed/16234821 http://dx.doi.org/10.1038/sj.bjc.6602820 |
Ejemplares similares
-
Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009) -
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007) -
Role of the extracellular matrix in COVID-19
por: Huang, Jia-Jia, et al.
Publicado: (2023) -
Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives
por: Garbuzenko, Dmitry Victorovich, et al.
Publicado: (2018) -
Extracellular Protein Fibulin-7 and Its C-Terminal Fragment Have In Vivo Antiangiogenic Activity
por: Ikeuchi, Tomoko, et al.
Publicado: (2018)